Document is current
Any future updates will be listed below
-
Authors
Verbeek, Joost G. E.
de Jong, Vincent M. T.
Wijnja, Hanna M.
Jager, Agnes
Linn, Sabine C.
Retèl, Valesca P. http://orcid.org/0000-0002-5624-3234
van Harten, Wim H.
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (NKI2014-7052)
ZonMw (843004015)
- License Information
-
More Information
Article History
Received: 1 March 2022
Accepted: 5 December 2022
First Online: 7 January 2023
Declarations
:
: This study received ethics approval by means of the protocol of the SUBITO trial (NCT02810743), the Netherlands Cancer Institute, the Netherlands, Amsterdam<b>.</b> All indivduals consented to participate in this study.
: Not applicable.
: SL receives research funding to her institution from Agendia, AstraZeneca, Eurocept-pharmaceuticals, Genentech, GSK (formerly Tesaro), Immunomedics, Merck, Novartis, Roche; has acted as a consultant (not compensated) for Cergentis and Philips Health; has acted as a consultant (paid to her institution) for AstraZeneca and IBM; has received educational funding to her institution from Bayer and Daiichi-Sankyo. In addition, SL has a patent UN23A01/P-EP pending. VR and WvH received unrestricted research grants from Agendia BV and Intuitive BV, outside the scope of the current research. The other authors declare that they have no conflict of interest.
